[P18C] Human High Density Lipoprotein 3 (HDL-3), 50% glycerol

[P18C] Human High Density Lipoprotein 3 (HDL-3), 50% glycerol

80P-HD3-101

Academy Bio-Medical Company, Inc.

  • $170.00


Concentration: 1 mg / ml, determined by the Lowry method
Source: From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.
Purification: After series ultracentrifugations, High Density Lipoprotein (HDL) is isolated from human plasma (density 1.121 - 1.210).
Buffer: 20 mM Tris-HCl, 140 mM NaCl, 0.02 % NaN3, 0.5 mM EDTA, pH 8.0. Preserved with 50 % glycerol.
Storage: - 20ºC for long and short - term storage

 

*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Density-gradient ultracentrifugation divides whole HDL into subclasses with increasing density, known as HDL2 and HDL3. According to the density, HDL (density 1.063-1.210) contains two major subfractions: HDL-2(density: 1.063-1.120) and HDL-3 (density: 1.120-1.210). In a prospective study, HDL2 showed a stronger inverse association with ischemic heart disease risk than did HDL3 (Gofman et al., 1966).

Study has shown that levels of both HDL2 and total HDL were inversely associated with the risk of acute myocardial infarction, suggesting that these forms of HDL may play a protective role in ischemic heart disease (Salonen et al., 1991).

The role of HDL3 remains equivocal, although small, dense HDL3 has been shown to protect low-density lipoprotein (LDL) from oxidative stress (Kontush and Chapman, 2006). In addition, lipid assessment in vascular disease can be simplified by measurement of either total or HDL cholesterol levels (Collaboration*, 2012).

Collaboration*, The Emerging Risk Factors. "Major Lipids, Apolipoproteins, and Risk of Vascular Disease." Jama 302.18 (2009): 1993.

Gofman, J. W.; Young, W.; Tandy, R., Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34, 679-97.

Kontush, A.; Chapman, M. J., Antiatherogenic small, dense HDL--guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3, 144-53.

Salonen, J. T., R. Salonen, K. Seppanen, R. Rauramaa, and J. Tuomilehto. "HDL, HDL2, and HDL3 Subfractions, and the Risk of Acute Myocardial Infarction. A Prospective Population Study in Eastern Finnish Men." Circulation 84.1 (1991): 129-39.

 

Citations

[P18A][P18B][P18C] 2018 Lutomski, Corinne A.; Gordon, Scott M.; Remaley, Alan T.; Jarrold, Martin F. (2018): Resolution of Lipoprotein Subclasses by Charge Detection Mass Spectrometry. In Anal. Chem. 90 (11), pp. 6353–6356. DOI: 10.1021/acs.analchem.8b01127.
[P18A][P18B][P18C] 2015 Cameron, Scott J.; Morrell, Craig N.; Bao, Clare; Swaim, AnneMarie F.; Rodriguez, Annabelle; Lowenstein, Charles J. (2015): A Novel Anti-Inflammatory Effect for High Density Lipoprotein. In PLoS ONE 10 (12), e0144372. DOI: 10.1371/journal.pone.0144372.
[P18A][P18B][P18C] 2014 Braesch-Andersen, Sten; Beckman, Lena; Paulie, Staffan; Kumagai-Braesch, Makiko (2014): ApoD mediates binding of HDL to LDL and to growing T24 carcinoma. In PLoS ONE 9 (12), e115180. DOI: 10.1371/journal.pone.0115180.

We Also Recommend